Hemostatic resuscitation in postpartum hemorrhage - A supplement to surgery

Acta Obstetricia et Gynecologica Scandinavica

Volumn 94, Issue 7, 2015, Pages 680-692

  Ekelund, Kim ^a   Hanke, Gabriele ^a   Stensballe, Jakob ^a,b   Wikkelsøe, Anne ^c   Albrechtsen, Charlotte Krebs ^a   Afshari, Arash ^a  

^a University of Copenhagen   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

fibrinogen; maternal morbidity; Postpartum hemorrhage; standard laboratory tests; tranexamic acid; transfusion strategy; viscoelastic hemostatic assays

Indexed keywords

ANTIVITAMIN K; DESMOPRESSIN; FIBRINOGEN; FIBRINOGEN CONCENTRATE; FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; UTEROTONIC AGENT; ANTIFIBRINOLYTIC AGENT; ARGIPRESSIN[1 DEAMINO]; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 7A; CRYSTALLOID; HEMOSTATIC AGENT; ISOTONIC SOLUTION; PROTHROMBIN COMPLEX CONCENTRATES; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

BLOOD CLOTTING; BLOOD EXAMINATION; BLOOD SUBSTITUTION; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; COCHRANE LIBRARY; CRYOPRECIPITATE; EMBASE; FIBRIN CLOT; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HYPOFIBRINOGENEMIA; LABORATORY TEST; MATERNAL MORBIDITY; MEDLINE; POSTPARTUM HEMORRHAGE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; REVIEW; ROTATIONAL THROMBOELASTOMETRY; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPH; THROMBOELASTOGRAPHY; BLOOD CLOTTING TEST; FEMALE; PREGNANCY;

ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; BLOOD TRANSFUSION; DEAMINO ARGININE VASOPRESSIN; FACTOR VIIA; FEMALE; FIBRINOGEN; HEMOSTATICS; HUMANS; ISOTONIC SOLUTIONS; POSTPARTUM HEMORRHAGE; PREGNANCY; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY; TRANEXAMIC ACID;

EID: 84930417300     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/aogs.12607     Document Type: Review

References (146)

1. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF,. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006; 367: 1066-74.
2. Knight M, Callaghan WM, Berg C, Alexander S, Bouvier-Colle M-H, Ford JB, et al., Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth. 2009; 9: 55.
3. Sheldon WR, Blum J, Vogel JP, Souza JP, Gülmezoglu AM, Winikoff B,. Postpartum haemorrhage management, risks, and maternal outcomes: findings from the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG. 2014; 121 (Suppl): 5-13.
4. Anderson JM, Etches D,. Prevention and management of postpartum hemorrhage. Am Fam Physician. 2007; 75: 875-82.
5. James AH, McLintock C, Lockhart E,. Postpartum hemorrhage: when uterotonics and sutures fail. Am J Hematol. 2012; 87: S16-22.
6. Szecsi PB, Jørgensen M, Klajnbard A, Andersen MR, Colov NP, Stender S,. Haemostatic reference intervals in pregnancy. Thromb Haemost. 2010; 103: 718-27.
7. Karlsson O, Sporrong T, Hellgren M,. Prospective longitudinal study of thromboelastography and standard hemostatic laboratory tests in healthy women during normal pregnancy. Anesth Analg. 2012; 115: 890-8.
8. Hellgren M,. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003; 29: 125-30.
9. Uchikova EH, Ledjev II,. Changes in haemostasis during normal pregnancy. Eur J Obstet Gynecol Reprod Biol. 2005; 119: 185-8.
10. O'Riordan MN,. Haemostasis in normal and abnormal pregnancy. Best Pract Res Clin Obstet Gynaecol. 2003; 17: 385-96.
11. Kozek-Langenecker SA,. Perioperative coagulation monitoring. Best Pract Res Clin Anaesthesiol. 2010; 24: 27-40.
12. Charbit B, Mandelbrot L, Samain E, Baron G, Haddaoui B, Keita H, et al., The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost. 2007; 5: 266-73.
13. Butwick A, Ting V, Ralls LA, Harter S, Riley E,. The association between thromboelastographic parameters and total estimated blood loss in patients undergoing elective cesarean delivery. Anesth Analg. 2011; 112: 1041-7.
14. Ahonen J, Stefanovic V, Lassila R,. Management of post-partum haemorrhage. Acta Anaesthesiol Scand. 2010; 54: 1164-78.
15. Cortet M, Deneux-Tharaux C, Dupont C, Colin C, Rudigoz R-C, Bouvier-Colle M-H, et al., Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial. Br J Anaesth. 2012; 108: 984-9.
16. Solomon C, Collis RE, Collins PW,. Haemostatic monitoring during postpartum haemorrhage and implications for management. Br J Anaesth. 2012; 109: 851-63.
17. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CAA, De Robertis E, Filipescu DC, et al., Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013; 30: 270-382.
18. Royal College of Obstetricians and Gynaecologists. RCOG Green-top Guideline No 52. Prevention and management of postpartum haemorrhage. Available online at: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg52/ (accessed 14 February 2015).
19. Fenger-Eriksen C, Moore GW, Rangarajan S, Ingerslev J, Sørensen B,. Fibrinogen estimates are influenced by methods of measurement and hemodilution with colloid plasma expanders. Transfusion. 2010; 50: 2571-6.
20. De Lloyd L, Bovington R, Kaye A, Collis RE, Rayment R, Sanders J, et al., Standard haemostatic tests following major obstetric haemorrhage. Int J Obstet Anesth. 2011; 20: 135-41.
21. Ganter MT, Hofer CK,. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg. 2008; 106: 1366-75.
22. Enriquez LJ, Shore-Lesserson L,. Point-of-care coagulation testing and transfusion algorithms. Br J Anaesth. 2009; 103: i14-22.
23. Chitlur M, Lusher J,. Standardization of thromboelastography: values and challenges. Semin Thromb Hemost. 2010; 36: 707-11.
24. Stensballe J, Ostrowski SR, Johansson PI,. Viscoelastic guidance of resuscitation. Curr Opin Anaesthesiol. 2014; 27: 212-8.
25. Oudghiri M, Keita H, Kouamou E, Boutonnet M, Orsini M, Desconclois C, et al., Reference values for rotation thromboelastometry (ROTEM®) parameters following non-haemorrhagic deliveries. Correlations with standard haemostasis parameters. Thromb Haemost. 2011; 106: 176-8.
26. De Lange NM, van Rheenen-Flach LE, Lancé MD, Mooyman L, Woiski M, van Pampus EC, et al., Peri-partum reference ranges for ROTEM® thromboelastometry. Br J Anaesth. 2014; 112: 852-9.
27. Armstrong S, Fernando R, Ashpole K, Simons R, Columb M,. Assessment of coagulation in the obstetric population using ROTEM® thromboelastometry. Int J Obstet Anesth. 2011; 20: 293-8.
28. Sharma S, Philip J, Wiley J,. Thromboelastographic changes in healthy parturients and postpartum women. Anesth Analg. 1997; 85: 94-8.
29. Steer PL, Krantz HB,. Thromboelastography and Sonoclot analysis in the healthy parturient. J Clin Anesth. 1993; 5: 419-24.
30. Huissoud C, Carrabin N, Benchaib M, Fontaine O, Levrat A, Massignon D, et al., Coagulation assessment by rotation thrombelastometry in normal pregnancy. Thromb Haemost. 2009; 101: 755-61.
31. De Lange NM, Lancé M, de Groot R, Beckers E, Henskens Y, Scheepers HCJ,. Obstetric Hemorrhage and coagulation: an update. thromboelastography, thromboelastometry, and conventional coagulation tests in the diagnosis and prediction of postpartum hemorrhage. Obstet Gynecol Surv. 2012; 67: 426-35.
32. Huissoud C, Carrabin N, Audibert F, Levrat A, Massignon D, Berland M, et al., Bedside assessment of fibrinogen level in postpartum haemorrhage by thrombelastometry. BJOG. 2009; 116: 1097-102.
33. Collins PW, Lilley G, Bruynseels D, Burkett-St Laurent D, Cannings-John R, Precious E, et al., Fibrin-based clot formation an early and rapidly available biomarker for progression of postpartum hemorrhage: a prospective cohort study. Blood. 2014; 124: 1727-36.
34. Annecke T, Geisenberger T, Kürzl R, Penning R, Heindl B,. Algorithm-based coagulation management of catastrophic amniotic fluid embolism. Blood Coagul Fibrinolysis. 2010; 21: 95-100.
35. Landers DF, Newland M, Penney LL,. Multiple uterine rupture and crushing injury of the fetal skull after blunt maternal trauma. A case report. J Reprod Med. 1989; 34: 988-93.
36. Harnett MJP, Hepner DL, Datta S, Kodali BS,. Effect of amniotic fluid on coagulation and platelet function in pregnancy: an evaluation using thromboelastography. Anaesthesia. 2005; 60: 1068-72.
37. Fries D, Innerhofer P, Klingler A, Berresheim U, Mittermayr M, Calatzis A, et al., The effect of the combined administration of colloids and lactated Ringer's solution on the coagulation system: an in vitro study using Thrombelastograph® coagulation analysis (ROTEG®). Anesth Analg. 2002; 94: 1280-7.
38. Butwick A, Carvalho B,. The effect of colloid and crystalloid preloading on thromboelastography prior to Cesarean delivery. Can J Anaesth. 2007; 54: 190-5.
39. Sharma S, Philip J, Whitten CW, Padakandla UB, Landers DF,. Assessment of changes in coagulation in parturients with preeclampsia using thromboelastography. Anesthesiology. 1990; 90: 385-90.
40. Hill JS, Devenie G, Powell M,. Point-of-care testing of coagulation and fibrinolytic status during postpartum haemorrhage: developing a thrombelastography®-guided transfusion algorithm. Anaesth Intensive Care. 2012; 40: 1007-15.
41. Afshari A, Wikkelsø A, Brok J, Am M, Wetterslev J,. Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion (Review). Cochrane Database Syst Rev. 2011; 3: CD007871.
42. Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, et al., 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg. 2011; 91: 944-82.
43. Weber CF, Gorlinger K, Meininger D, Herrmann E, Bingold T, Moritz A, et al., Point-of-care testing. Anesthesiology. 2012; 117: 531-47.
44. Fenger-Eriksen C, Ingerslev J, Sørensen B,. Fibrinogen concentrate-a potential universal hemostatic agent. Expert Opin Biol Ther. 2009; 9: 1325-33.
45. Bell SF, Rayment R, Collins PW, Collis RE,. The use of fibrinogen concentrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage. Int J Obstet Anesth. 2010; 19: 218-23.
46. Bolliger D, Szlam F, Levy JH, Molinaro RJ, Tanaka KA,. Haemodilution-induced profibrinolytic state is mitigated by fresh-frozen plasma: implications for early haemostatic intervention in massive haemorrhage. Br J Anaesth. 2010; 104: 318-25.
47. Schöchl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, et al., Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care. 2010; 14: R55.
48. Butwick AJ,. Postpartum hemorrhage and low fibrinogen levels: the past, present and future. Int J Obstet Anesth. 2013; 22: 87-91.
49. Ahmed S, Harrity C, Johnson S, Varadkar S, McMorrow S, Fanning R, et al., The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage-an observational study. Transfus Med. 2012; 22: 344-9.
50. Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, Ingerslev J, Sørensen B,. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth. 2008; 101: 769-73.
51. Weinkove R, Rangarajan S,. Fibrinogen concentrate for acquired hypofibrinogenaemic states. Transfus Med. 2008; 18: 151-7.
52. Levy JH, Welsby I, Goodnough LT,. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion. 2014; 54: 1389-405.
53. ASA. Practice guidelines for perioperative blood transfusion and adjuvant therapies. Anesthesiology. 2006; 105: 198-208.
54. Stinger HK, Spinella PC, Perkins JG, Grathwohl KW, Salinas J, Martini WZ, et al., The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma. 2008; 64: S79-85.
55. Hendrickson JE, Hillyer CD,. Noninfectious serious hazards of transfusion. Anesth Analg. 2009; 108: 759-69.
56. Rahe-Meyer N, Sørensen B,. For: fibrinogen concentrate for management of bleeding. J Thromb Haemost. 2011; 9: 1-5.
57. Sørensen B, Bevan D,. A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol. 2010; 149: 834-43.
58. Kozek-Langenecker S, Sørensen B, Hess JR, Spahn DR,. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care. 2011; 15: R239.
59. Wikkelsoe AJ, Afshari A, Stensballe J, Langhoff-Roos J, Albrechtsen C, Ekelund K, et al., Pre-emptive treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial. Br J Anaesth. 2015; doi: 10.1093/bja/aeu444 [Epub ahead of print].
60. Ahonen J,. Use of Prothrombin Complex Concentrate and Fibrinogen Compared With Fresh Frozen Plasma (and Fibrinogen if Needed) in the Treatment of Postpartum Haemorrhage. ClinicalTrials.gov registration number: NCT01910675. (accessed 29 January, 2015).
61. Lunde J, Stensballe J, Wikkelsø A, Johansen M, Afshari A,. Fibrinogen concentrate for bleeding-a systematic review. Acta Anaesthesiol Scand. 2014; 24: 1-14.
62. Warmuth M, Mad P, Wild C,. Systematic review of the efficacy and safety of fibrinogen concentrate substitution in adults. Acta Anaesthesiol Scand. 2012; 56: 539-48.
63. Girard T, Mörtl M, Schlembach D,. New approaches to obstetric hemorrhage: the postpartum hemorrhage consensus algorithm. Curr Opin Anaesthesiol. 2014; 27: 267-74.
64. Pacheco LD, Saade GR, Gei AF, Hankins GDV,. Cutting-edge advances in the medical management of obstetrical hemorrhage. Am J Obstet Gynecol. 2011; 205: 526-32.
65. Dunn CJ, Goa KL,. Tranexamic acid. A review of its use in surgery and other indications. Drugs. 1999; 57: 1005-32.
66. Goswami U, Sarangi S, Gupta S, Babbar S,. Comparative evaluation of two doses of tranexamic acid used prophylactically in anemic parturients for lower segment cesarean section: a double-blind randomized case control prospective trial. Saudi J Anaesth. 2013; 7: 427-31.
67. Sentürk MB, Cakmak Y, Yildiz G, Yildiz P,. Tranexamic acid for cesarean section: a double-blind, placebo-controlled, randomized clinical trial. Arch Gynecol Obstet. 2013; 287: 641-5.
68. Xu J, Gao W, Ju Y,. Tranexamic acid for the prevention of postpartum hemorrhage after cesarean section: a double-blind randomization trial. Arch Gynecol Obstet. 2013; 287: 463-8.
69. Gungorduk K, Asicioglu O, Yildirim G, Cemal A, Tekirdag A, Besimoglu B,. Can intravenous injection of tranexamic acid be used in routine practice with active management of the third stage of labor in vaginal delivery? A randomized controlled study. Am J Perinatol. 2013; 30: 407-13.
70. Gungorduk K, Yildirim G, Asiciog O,. Efficacy of intravenous tranexamic acid in reducing blood loss after elective cesarean section: a prospective, randomized, double-blind, placebo-controlled study. Am J Perinatol. 2011; 28: 233-9.
71. Movafegh A, Eslamian L, Dorabadi A,. Effect of intravenous tranexamic acid administration on blood loss during and after cesarean delivery. Int J Gynaecol Obstet. 2011; 115: 224-6.
72. Sekhavat L, Tabatabaii A, Dalili M, Farajkhoda T, Tafti AD,. Efficacy of tranexamic acid in reducing blood loss after cesarean section. J Matern Neonatal Med. 2009; 22: 72-5.
73. Gohel M, Patel P, Gupta A, Desai P,. Efficacy of tranexamic acid in decreasing blood loss during and after cesarean section: a randomized case controlled prospective study. J Obstet Gynecol India. 2007; 57: 227-30.
74. Gai M, Wu L, Su Q, Tatsumoto K,. Clinical observation of blood loss reduced by tranexamic acid during and after caesarean section: a multi-center, randomized trial. Eur J Obstet Gynecol Reprod Biol. 2004; 112: 154-7.
75. Yang H, Zheng S, Shi C,. [Clinical study on the efficacy of tranexamic acid in reducing postpartum blood lose: a randomized, comparative, multicenter trial]. Zhonghua Fu Chan Ke Za Zhi. 2001; 36: 590-2.
76. Novikova N, Hofmeyr G,. Tranexamic acid for preventing postpartum haemorrhage (Review). Cochrane Database Syst Rev. 2010; 7: CD007872.
77. Ducloy-Bouthors A-S, Jude B, Duhamel A, Broisin F, Huissoud C, Keita-Meyer H, et al., High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. Crit Care. 2011; 15: R117.
78. WHO Guidelines Approved by the Guidelines Review Committee. WHO recommendations for the prevention and treatment of postpartum haemorrhage. Geneva: WHO Press, 2012. http://apps.who.int/iris/bitstream/10665/75411/1/9789241548502-eng.pdf?ua=1 (accessed 14 February, 2015).
79. Roberts I, Shakur H, Ker K, Coats T,. Antifibrinolytic drugs for acute traumatic injury (Review). Cochrane Database Syst Rev. 2012; 12: CD004896.
80. Ferrer P, Roberts I, Sydenham E, Blackhall K, Shakur H,. Anti-fibrinolytic agents in post partum haemorrhage: a systematic review. BMC Pregnancy Childbirth. 2009; 9: 1-6.
81. Peitsidis P, Kadir RA,. Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert Opin Pharmacother. 2011; 12: 503-16.
82. Shakur H, Elbourne D, Gülmezoglu M, Alfirevic Z, Ronsmans C, Allen E, et al., Study protocol The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. Trials. 2010; 11: 1-14.
83. Samama CM,. Prothrombin complex concentrates: a brief review. Eur J Anaesthesiol. 2008; 25: 784-9.
84. McSwain N, Barbeau J,. Potential use of prothrombin complex concentrate in trauma resuscitation. J Trauma. 2011; 70: S53-6.
85. Johansen M, Wikkelsø A, Lunde J, Wetterslev J, Afshari A,. Prothrombin complex concentrate for perioperative reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients requiring acute surgical intervention (Protocol). Cochrane Database Syst Rev. 2013; 6: CD010555.
86. Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle C-E,. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Res. 2007; 121: 9-16.
87. Hanke AA, Joch C, Görlinger K,. Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. Br J Anaesth 2013; 18: 1-9.
88. Rochette A, Jullien Y, Cailar JDU,. Disseminated intravascular coagulation. Ann Fr Anesth Reanim. 1983; 2: 259-65.
89. Levi M, Eerenberg E, Kamphuisen PW,. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost. 2011; 9: 1705-12.
90. Sørensen B, Moore G, Hochleitner G, Fenger-Eriksen C,. Levels of fibrinogen and thromboelastometry fibrin polymerisation following treatment with desmopressin (DDAVP). Thromb Res. 2012; 129: e164-5.
91. Crescenzi G, Landoni G, Biondi-Zoccai G, Pappalardo F, Nuzzi M, Bignami E, et al., Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. Anesthesiology. 2008; 109: 1063-76.
92. Gurusamy K, Li J, Sharma D, Davidson K,. Pharmacological interventions to decrease blood loss and blood transfusion requirements for liver resection (Review). Cochrane Database Syst Rev. 2009; 4: CD008085.
93. Trigg DE, Stergiotou I, Peitsidis P, Kadir RA,. A systematic review: the use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia. 2012; 18: 25-33.
94. Hedner U,. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies. Thromb Haemost. 2008 Sep; 5: 557-62.
95. Poon M,. Use of recombinant factor VIIa in hereditary. Curr Opin Hematol. 2001; 8: 312-8.
96. Kale A, Bayhan G, Yalinkaya A, Yayla M,. The use of recombinant factor VIla in a primigravida with Glanzmann's thrombasthenia during delivery. J Perinat Med. 2004; 32: 456-8.
97. Kenet G, Walden R, Eldad A, Martinowitz U,. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999; 354: 1879.
98. Hedner U,. Mechanism of Action of factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost. 2006; 32: 77-85.
99. Gill R, Herbertson M,. Recombinant factor VIIa: a universal haemostatic agent? Ann Card Anaesth. 2006; 9: 97-9.
100. Ahonen J,. The role of recombinant activated factor VII in obstetric hemorrhage. Curr Opin Anaesthesiol. 2012; 25: 309-14.
101. Ahonen J, Jokela R, Korttila K,. An open non-randomized study of recombinant activated factor VII in major postpartum haemorrhage. Acta Anaesthesiol Scand. 2007; 51: 929-36.
102. Hossain N, Shansi T, Haider S, Soomro N, Khan NH, Memon GU, et al., Use of recombinant activated factor VII for massive postpartum hemorrhage. Acta Obstet Gynecol Scand. 2007; 86: 1200-6.
103. Franchini M, Franchi M, Bergamini V, Salvagno GL, Montagnana M, Lippi G,. A critical review on the use of recombinant factor VIIa in life-threatening obstetric postpartum hemorrhage. Semin Thromb Hemost. 2008; 34: 104-12.
104. Franchini M, Franchi M, Bergamini V, Montagnana M, Salvagno GL, Targher G, et al., The use of recombinant activated FVII in postpartum hemorrhage. Clin Obstet Gynecol. 2010; 53: 219-27.
105. Alfirevic Z, Elbourne D, Pavord S, Bolte A, Van Geijn H, Mercier F, et al., Use of recombinant activated factor VII in primary postpartum hemorrhage. Obstet Gynecol. 2007; 110: 1270-8.
106. Phillips LE, McLintock C, Pollock W, Gatt S, Popham P, Jankelowitz G, et al., Recombinant activated factor VII in obstetric hemorrhage: experiences from the Australian and New Zealand Haemostasis Registry. Anesth Analg. 2009; 109: 1908-15.
107. Barillari G, Frigo MG, Casarotto M, Farnia A, Massè B, Wetzl R, et al., Use of recombinant activated factor VII in severe post-partum haemorrhage: data from the Italian Registry: a multicentric observational retrospective study. Thromb Res. 2009; 124: e41-7.
108. Blatný J, Seidlová D, Penka M, Ovesná P, Brabec P, Sevčík P, et al., Severe postpartum haemorrhage treated with recombinant activated factor VII in 80 Czech patients: analysis of the UniSeven registry. Int J Obstet Anesth. 2011; 20: 367-8.
109. Sobieszczyk S, Breborowicz GH, Platicanov V, Tanchev S, Kessler CM,. Recombinant factor VIIa in the management of postpartum bleeds: an audit of clinical use. Acta Obstet Gynecol Scand. 2006; 85: 1239-47.
110. Leduc D, Senikas V, Lalonde AB, Ballerman C, Biringer A, Delaney M, et al., Active management of the third stage of labour: prevention and treatment of postpartum hemorrhage. Int J Gynecol Obstet. 2010; 108: 258-67.
111. Welsh A, McLintock C, Gatt S, Somerset D, Popham P, Ogle R,. Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage. Aust N Z J Obstet Gynaecol. 2008; 48: 12-6.
112. ACOG Committee on Practice Obstetrics, Zelop CM, Herbert WNP,. PRACTICE BULLETIN. Obstet Gynecol. 2006; 108: 1039-47.
113. Gris J-G,. Recombinant Human Activated Factor VII as Salvage Therapy in Women With Severe Postpartum Hemorrhage. Registration number: NCT00370877. ClinicalTrials.gov (accessed 29 January 2015).
114. Factor R, Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K,. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med. 2011; 154: 529-40.
115. Levi M, Levy JH, Andersen HF, Truloff D,. Safety of recombinant activated Factor VII in randomized clinical trials. N Engl J Med. 2011; 363: 1791-800.
116. Rath WH,. Postpartum hemorrhage-update on problems of definitions and diagnosis. Acta Obstet Gynecol Scand. 2011; 90: 421-8.
117. Mousa HA, Walkinshaw S,. Major postpartum haemorrhage. Curr Opin Obstet Gynecol. 2001; 13: 595-603.
118. Johansson PI, Ostrowski SR, Secher NH,. Management of major blood loss: an update. Acta Anaesthesiol Scand. 2010; 54: 1039-49.
119. Ickx BE,. Fluid and blood transfusion management in obstetrics. Eur J Anaesthesiol. 2010; 27: 1031-5.
120. Nielsen VG,. Colloids decrease clot propagation and strength: role of factor XIII-fibrin polymer and thrombin-fibrinogen interactions. Acta Anaesthesiol Scand. 2005; 49: 1163-71.
121. Solomonov E, Hirsh M, Yahiya A, Krausz MM,. The effect of vigorous fluid resuscitation in uncontrolled hemorrhagic shock after massive splenic injury. Crit Care Med. 2000; 28: 749-54.
122. Farber MK, Sadana N, Kaufman RM, Liu X, Kodali BS,. Transfusion ratios for postpartum hemodilutional coagulopathy: an in vitro thromboelastographic model. Am J Obstet Gynecol. 2014; 20: 323.e1-7.
123. Gaarder C, Naess PA, Frischknecht Christensen E, Hakala P, Handolin L, Stensballe J,. Scandinavian Guidelines-"the massively bleeding patients." Scand J Surg. 2008; 97: 15-36.
124. Holcomb JB, del Junco DJ, Fox EE, Wade CE, Cohen MJ, Schreiber MA, et al., The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg. 2013; 148: 127-36.
125. Jansen JO, Thomas R, Loudon MA, Brooks A,. Damage control resuscitation for patients with major trauma. BMJ. 2009; 338: b1778.
126. Borgman MA, Spinella PC, Perkins JG, Grathwohl KW, Repine T, Beekley AC, et al., The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma. 2007; 63: 805-13.
127. Holcomb JB, Wade CE, Michalek JE, Chisholm GB, Zarzabal LA, Schreiber MA, et al., Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg. 2008; 248: 447-58.
128. Baraniuk S, Tilley BC, del Junco DJ, Fox EE, van Belle G, Wade CE, et al., Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: Design, rationale and implementation. Injury. 2014; 45: 1287-95.
129. Pasquier P, Gayat E, Rackelboom T, La Rosa J, Tashkandi A, Tesniere A, et al., An observational study of the fresh frozen plasma: red blood cell ratio in postpartum hemorrhage. Anesth Analg. 2013; 116: 155-61.
130. Saule I, Hawkins N,. Transfusion practice in major obstetric haemorrhage: lessons from trauma. Int J Obstet Anesth. 2011; 21: 79-83.
131. Xue X, Liu L, Rao Z,. Management of postpartum hemorrhagic shock and disseminated intravascular coagulation with damage control resuscitation. Am J Emerg Med. 2013; 31: 1291.e1-2.
132. James AH, Paglia MJ, Gernsheimer T, Grotegut C, Thames B,. Blood component therapy in postpartum hemorrhage. Transfusion. 2009; 49: 2430-3.
133. Bonnet M-P, Deneux-Tharaux C, Dupont C, Rudigoz R-C, Bouvier-Colle M-H,. Transfusion practices in postpartum hemorrhage: a population-based study. Acta Obstet Gynecol Scand. 2013; 92: 404-13.
134. Al-Zirqi I, Vangen S, Forsen L, Stray-Pedersen B,. Prevalence and risk factors of severe obstetric haemorrhage. BJOG. 2008; 115: 1265-72.
135. Johansson PI, Stensballe J,. Effect of haemostatic control resuscitation on mortality in massively bleeding patients: a before and after study. Vox Sang. 2009; 96: 111-8.
136. Prick B, Jansen A, Steegers E, Hop W, Essink-Bot M, Uyl-de Groot C, et al., Transfusion policy after severe postpartum haemorrhage: a randomised non-inferiority trial. BJOG 2014; 00: 1-10.
137. Rohde JM, Dimcheff DE, Blumberg N, Saint S, Langa KM, Kuhn L, et al., Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA. 2014; 311: 1317-26.
138. Bolton-Maggs PP, Poles D, Watt A, Thomas D, Cohen H, Davies T, et al., Annual SHOT Report 2013. Available online at: www.shotuk.org/wp-content/uploads/74280-SHOT-2014-Annual-Report-V12-WEB.pdf. (accessed 14 February, 2015).
139. Yang Lucy, Sally H, Doree C, Murphy M,. Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials. Transfusion. 2012; 52: 1673-86.
140. Shanwell A, Andersson TM-L, Rostgaard K, Edgren G, Hjalgrim H, Norda R, et al., Post-transfusion mortality among recipients of ABO-compatible but non-identical plasma. Vox Sang. 2009; 96: 316-23.
141. Watson GA, Sperry JL, Rosengart MR, Minei JP, Harbrecht BG, Moore EE, et al., Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. J Trauma. 2009; 67: 221-7.
142. Williamson LM, Lowe S, Love EM, Cohen H, Soldan K, McClelland DB, et al., Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports. BMJ. 1999; 319: 16-9.
143. Rainaldi MP, Tazzari PL, Scagliarini G, Borghi B, Conte R,. Blood salvage during caesarean section. Br J Anaesth. 1998; 80: 195-8.
144. Geoghegan J, Daniels JP, Moore PAS, Thompson PJ, Khan KS, Gülmezoglu AM,. Cell salvage at caesarean section: the need for an evidence-based approach. BJOG. 2009; 116: 743-7.
145. Malik S, Brooks H, Singhal T,. Cell saver use in obstetrics. J Obstet Gynaecol. 2010; 30: 826-8.
146. Johansson PI, Stensballe J, Ostrowski SR,. Current management of massive hemorrhage in trauma. Scand J Trauma Resusc Emerg Med. 2012; 20: 1-10.